Ocugen's Gene Therapy Ambitions Fueled by Clinical and Financial Milestones

Ocugen accelerates its gene therapy pipeline, completing dosing for a Stargardt disease trial early and advancing two other programs toward Phase 3 and BLA submissions by 2027.

Ocugen Inc. has accelerated the development of its gene therapy pipeline, hitting a key clinical target ahead of schedule. The biotech firm announced the completion of dosing in its pivotal Phase 2/3 GARDian3 trial for OCU410ST, a treatment for Stargardt disease, in under nine months. This inherited retinal disorder, affecting an estimated 100,000 people in the US and Europe, currently has no FDA-approved therapy. The trial enrolled 63 patients.

The company’s progress is not limited to a single candidate. For its lead asset, OCU400 targeting retinitis pigmentosa, patient recruitment for the Phase 3 liMeliGhT study is finished. This keeps Ocugen on track to submit a rolling Biologics License Application (BLA) in the third quarter of 2026. A third program, OCU410 for dry age-related macular degeneration, demonstrated a favorable safety profile and is slated to enter Phase 3 trials also in Q3 2026.

Underpinning the optimism for OCU410ST are data from an earlier Phase 1 study. That trial showed a 54% reduction in the growth of atrophic lesions in treated eyes compared to untreated fellow eyes over twelve months. On average, treated eyes gained 6 letters in best-corrected visual acuity, while untreated eyes lost 1.5 letters. No serious adverse events have been reported to date.

Financing this ambitious clinical push has been a focus. Ocugen bolstered its balance sheet with a $22.5 million capital raise in January 2026. Combined with a cash position of $18.9 million at the end of 2025, this provides an operational runway through the fourth quarter of 2026. The company notes that if all outstanding warrants are fully exercised, liquidity could extend into the second quarter of 2027.

Wall Street has taken note of these developments. In March 2026, two investment banks initiated coverage with bullish ratings. Canaccord Genuity issued a "Buy" rating with a $12.00 price target, while Oppenheimer started coverage with an "Outperform" rating and a $10.00 target.

The clinical calendar is now densely packed with upcoming catalysts. An interim analysis for the GARDian3 trial is expected in Q3 2026, once 24 patients complete eight months of follow-up. Topline data from the Phase 3 OCU400 study are anticipated in Q1 2027, followed by GARDian3 topline results in Q2 2027. Ocugen aims to submit its BLA for OCU410ST by mid-2027.

Management's overarching strategy is to file three BLAs for different gene therapy programs targeting inherited retinal diseases by 2028. Investors will get a further update on the company's financial health with the release of its quarterly report in May 2026.